Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics

Kuttler, Andreas; Dimke, Thomas

doi:10.1183/13993003.congress-2015.pa3582

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Breezhaler Ò was designed to provide immediate sensory feedback to the patient that the dose has been administered correctly: by hearing a distinctive ''whirring'' noise on correct inhalation, by visually checking that the transparent drug capsule is empty, and by tasting the lactose excipient [38]. The Breezhaler Ò has a low intrinsic resistance; most patients are able to generate the minimum inspiratory flow rate of 30 L/min with Breezhaler Ò and the device provides consistent dose delivery using inspiratory flow rates between 30 and 100 L/min [39][40][41]. Low-resistance devices such as Breezhaler Ò allow air to flow through them easily [41].…”

Section: Breezhaler òmentioning

confidence: 99%

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

et al. 2019

View full text Add to dashboard Cite

Inhaled fixed-dose combinations (FDCs) of a long-acting b-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have recognized the importance of inhaler devices as integral contributors to the effectiveness of LABA/ LAMA FDCs and recommend regular assessment of inhaler device use by the patients in order to improve long-term clinical outcomes. Optimal disease control is also highly dependent upon patient preferences and adherence to inhaler devices. This review objectively examines and compares the major inhaler devices used to deliver different LABA/LAMA FDCs, discusses the inhaler device characteristics that determine drug deposition in the airways, real-life preference for inhaler devices, and handling of inhaler devices that impact the results of the long-term management of COPD. The introduction of new LABA/LAMA FDCs, new inhaler devices, and more clinical studies have created confusion among physicians in choosing the optimal inhaled therapy for COPD patients; in this context, this review attempts to provide an evidencebased framework for informed decision-making with a particular focus on the inhaler devices. Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.7776272.

show abstract